A systematic review and meta-analysis of family history and risk of ovarian cancer

British Journal of Obstetrics and Gynaecology
J F StrattonB A Ponder

Abstract

To estimate the relative risk and lifetime risk of ovarian cancer in women with various categories of family history. A meta-analysis of all published case-control and cohort studies. Pooled relative risk estimates were calculated for the case control studies, using the Mantel-Haenzel method. These estimates were combined with the relative risks from the cohort studies. The pooled estimates of relative risk were used to estimate lifetime risks of ovarian cancer from age 15 up to age 75, for various categories of family history. Relative risks and lifetime risks of developing ovarian cancer were calculated for the categories of women with 1. an affected first degree relative; 2. an affected mother; 3. an affected sister; and 4. women with more than one affected relative. The relative risk to first degree relatives is 3.1 (95% CI 2.6-3.7). There is some evidence that this relative risk declines with age. The relative risk to mothers of cases 1.1 (95% CI 0.8-1.6) was lower than the relative risks to sisters: 3.8 (95% CI 2.9-5.1), and daughters: 6.0 (95% CI 3.0-11.9); the explanation of this difference is unclear. Women with a family history of ovarian cancer have a substantially higher risk of developing ovarian cancer compared wi...Continue Reading

References

Jul 28, 1979·Lancet·J T CasagrandeB E Henderson
Nov 1, 1992·Gynecologic Oncology·R HoulstonJ Slack
Jan 1, 1992·American Journal of Epidemiology·F ParazziniS Franceschi
Dec 1, 1989·International Journal of Epidemiology·M KochH Jenkins
Jul 1, 1989·American Journal of Obstetrics and Gynecology·P HartgeH J Norris
Sep 1, 1988·American Journal of Epidemiology·J M Schildkraut, W D Thompson
Aug 1, 1984·European Journal of Cancer & Clinical Oncology·A TzonouA Polychronopoulou
Sep 1, 1981·American Journal of Epidemiology·N G HildrethC White
Sep 15, 1995·International Journal of Cancer. Journal International Du Cancer·D PurdieB Susil
May 8, 1995·Archives of Internal Medicine·R A Kerber, M L Slattery
Nov 2, 1994·Journal of the National Cancer Institute·D E GoldgarM H Skolnick
Apr 1, 1994·American Journal of Epidemiology·L RosenbergS Shapiro
Jan 26, 1996·International Journal of Cancer. Journal International Du Cancer·D F EastonJ Peto
Jul 1, 1996·British Journal of Cancer·A AuranenT Salmi
Apr 17, 1997·The New England Journal of Medicine·J F StrattonB A Ponder

❮ Previous
Next ❯

Citations

Dec 10, 2002·International Journal of Cancer. Journal International Du Cancer·Annika AuranenKaren L Novik
Jan 17, 2008·Cancer Causes & Control : CCC·Marie SoegaardSusanne K Kjaer
Feb 27, 2004·Gynecologic Oncology·Alessandra TavaniCarlo La Vecchia
May 20, 2003·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E NegriC La Vecchia
Mar 31, 2000·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·K Hemminki, C Dong
Apr 16, 2009·European Journal of Human Genetics : EJHG·D Gareth R EvansFiona Lalloo
Mar 29, 2013·Nature Genetics·Paul D P PharoahThomas A Sellers
Oct 4, 2011·Nature Genetics·Thorunn RafnarKari Stefansson
Apr 2, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P M L H VenckenC Seynaeve
Nov 15, 2011·Genetics in Medicine : Official Journal of the American College of Medical Genetics·Wendy S RubinsteinUNKNOWN Family Healthware Impact Trial (FHITr) Group
Jun 10, 2000·Quality in Health Care : QHC·A MelvilleL Nelson
Jan 25, 2013·International Journal of Molecular Sciences·Dominic VargaLisa Wiesmüller
Mar 6, 2012·Familial Cancer·Anne M van AltenaJoanne A de Hullu
May 13, 2003·International Journal of Cancer. Journal International Du Cancer·Kari Hemminki, Charlotta Granström
Sep 25, 2015·Genetic Epidemiology·Ernest K AmankwahCatherine M Phelan
Dec 8, 2000·Journal of Obstetric, Gynecologic, and Neonatal Nursing : JOGNN·K Furniss
Mar 1, 2012·Best Practice & Research. Clinical Obstetrics & Gynaecology·Greta Dreyer
May 12, 2010·Current Opinion in Genetics & Development·Simon A Gayther, Paul D P Pharoah
Jun 7, 2007·Mayo Clinic Proceedings·Giovanni D AlettiLynn C Hartmann
Mar 18, 2004·Clinical Colorectal Cancer·Nader N Hanna, Alfred M Cohen
Jul 29, 2008·Critical Reviews in Oncology/hematology·Antonio RussoGaetana Di Fede
Feb 13, 2010·The Journal of Obstetrics and Gynaecology Research·Dai KomataKenichi Tanaka
Aug 11, 2007·Human Mutation·Susan J RamusSimon A Gayther
Nov 19, 2005·Journal of the American Academy of Nurse Practitioners·Amy N BrunsvoldCarrie J Merkle
Oct 20, 2015·Molecular Diagnosis & Therapy·Elisabete Weiderpass, Jerzy E Tyczynski
Sep 29, 2004·American Journal of Preventive Medicine·Harvey J MurffSapna Syngal
Oct 5, 2006·Critical Reviews in Oncology/hematology·Nicoletta ColomboIgnace Vergote
May 25, 2012·Schizophrenia Research·Gilad GalItzhak Levav
Nov 5, 2002·Best Practice & Research. Clinical Obstetrics & Gynaecology·Paul D P Pharoah, Bruce A J Ponder
Apr 23, 2009·Molecular Oncology·Susan J Ramus, Simon A Gayther

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.